drugset / Trial / NCT04956432
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to Allopurinol in subjects with gout.
Timeline
- Start
- 2021-06-15
- Primary completion
- 2023-12-13
- Completion
- 2024-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Allopurinol | Small molecule | 300 mg | Oral |
| Subject | SHR4640 | Small molecule | — | Oral |